bêta
IA Trial Radar
L'essai clinique NCT06744491 (NFRF) pour Inactivité physique, Vieillissement, Vieillissement en bonne santé, Growth & Development, Différences sexuelles, Anabolic Sensitivity, Protein Metabolism, Activité physique est pas encore en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Oral 'Breath Test' to Measure Anabolic Sensitivity to a Protein Meal Across the Age and Physical Activity Spectrum (NFRF)

Pas encore en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06744491 (NFRF) est un essai observationnel pour Inactivité physique, Vieillissement, Vieillissement en bonne santé, Growth & Development, Différences sexuelles, Anabolic Sensitivity, Protein Metabolism, Activité physique. Son statut actuel est : pas encore en recrutement. Le recrutement est prévu pour commencer le 20 décembre 2024, avec un objectif de 80 participants. Dirigé par l'Université de Toronto, l'essai devrait être terminé d'ici le 31 août 2025. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 20 décembre 2024.
Résumé succinct
The purpose of this study is to determine how anabolic sensitivity, in response to the ingestion of a liquid protein meal, differs across the lifespan, between biological sexes, and with varying physical activity levels.
Description détaillée
Skeletal muscle is a dynamic tissue that responds to anabolic (i.e., growth) stimuli such as protein ingestion and exercise. Differences in age and physical activity levels will influence an individual's ability to respond to these anabolic stimuli; this concept is known as anabolic sensitivity. For instance, older and less physically active individuals will display lower anabolic sensitivity (i.e., anabolic resistance) to a bout of exercise or the consumption of protein in comparison to younger, more physically active individuals. Seeing that individuals with anabolic resistance are at a greater risk for losing muscle mass over time, it is important to understand the anabolic sensitivity/resistance of an individual to assess for the efficiency of growth across the health and lifespan, in addition to a potential screen for metabolic alterations that could manifest into changes in lean body and muscle mass.

Traditional methods to assess for skeletal muscle anabolism and protein metabolism requires in-person and invasive research methods (i.e., stable isotope infusions and muscle biopsies) in controlled laboratory or clinical settings. However, there are many risks associated with these invasive procedures and they are not always feasible in all populations (e.g., children, clinical populations, etc..). Our lab has recently developed a non-invasive 13C breath test which employs an oral stable isotope tracer. Our breath test allows us to assess for anabolic sensitivity in response to protein ingestion, by determining how much of the ingested protein was used to build (synthesize) new proteins in our body (i.e., anabolism) or used as a source of energy (through a process called oxidation). As such, the purpose of the present study is to determine how anabolic sensitivity, in response to the ingestion of a liquid protein meal, differs across the lifespan and with varying physical activity levels.

Titre officiel

Anabolic Sensitivity Across the Lifespan

Conditions
Inactivité physiqueVieillissementVieillissement en bonne santéGrowth & DevelopmentDifférences sexuellesAnabolic SensitivityProtein MetabolismActivité physique
Autres identifiants de l'essai
  • NFRF
  • 00044004
Numéro NCT
Date de début (réel)
2024-12-20
Dernière mise à jour publiée
2024-12-20
Date de fin (estimée)
2025-08-31
Inscription (estimée)
80
Type d'essai
Observationnel
Statut
Pas encore en recrutement
Mots clés
anabolic sensitivity
aging
growth and development
physical activity
skeletal muscle
stable isotopes
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Children
Children as defined by maturity offset via age from peak height velocity (aPHV \< -1.0 years).
N/A
Adolescent
Adolescents as defined by maturity offset via age from peak height velocity (aPHV -0.5 to +1.5 years)
N/A
Young Adults
Young adults as defined by chronological age between ages 18 - 35 years
N/A
Older Adults
Older adults as defined by chronological age between ages 60 - 80 years
N/A
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Amino acid oxidation and net protein balance
Amino acid oxidation and net protein balance assessed by oral 1-13C Leucine tracer. Net protein balance is derived from the difference between amino acid intake (known) and total amino acid oxidation over the 6h post-prandial measurement period.
6 Hours
Critères d'éligibilité

Âges éligibles
Enfant, Adulte, Adulte âgé
Âge minimum
8 Years
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui
  • Healthy will be defined as screened by the PAR-Q+ (The Physical Activity Readiness Questionnaire for everyone)
  • Chronological age for Healthy Young (age: 18-35 years) or Older (age: 60-80 years) adults
  • Chronological age between 8 to 16 years, with maturity offset < -1 year from age of Peak Height Velocity (aPHV) for children and between -0.5 to +1.5 years from aPHV in adolescent participants
  • BMI between normal to overweight (18.5 - 29.9 kg/m2)

  • Regular use of nonsteroidal anti-inflammatory dugs (with the exception of daily low-dose aspirin)
  • use of anticoagulants
  • use of a walker, cane, or assistive walking device
  • infectious or gastrointestinal disease
  • inability to comply with study protocol (e.g., unable to track diet)
  • regular tobacco use
  • self-reported illicit drug use (e.g., growth hormone, testosterone, etc.)
  • diagnosed chronic illness (e.g., type 2 diabetes, heart disease, thyroid disease)
  • pregnant
  • hormonal replacement therapy
Partie responsable de l'essai
Daniel Moore, Investigateur principal, Professor, Muscle Physiology, University of Toronto
Contact central de l'essai
Contact: Daniel R Moore, PhD, 4169464088, [email protected]
Contact: Hugo JW Fung, PhD Candidate, [email protected]
1 Centres de l'essai dans 1 pays

Ontario

Goldring Center for High Performance Sport, Toronto, Ontario, M5S 2C9, Canada
Hugo JW Fung, PhD Candidate, Contact, 416-946-5620, [email protected]